Judge Blocks Merck's Challenge to Medicare Drug Price Negotiations

US District Court Judge Colleen Kollar-Kotelly rejected Merck & Co.'s bid to overturn Medicare's drug price negotiations, handing the program a significant victory. The ruling comes after three years of litigation, with the court finding that there is no genuine dispute over material facts in the case. This decision marks a crucial milestone for the embattled program, which has faced numerous challenges since its inception.

Merck had argued that it could withdraw from the program and sell its selected drug at its own desired price on the private market. However, Judge Kollar-Kotelly disagreed, citing previous court decisions that have dealt with similar challenges to the Program. The ruling effectively upholds the authority of Medicare to negotiate prices with pharmaceutical companies.

The decision is significant not only for Merck but also for the broader healthcare industry, as it sets a precedent for future challenges to the program. As the first challenge to be filed against the program, this ruling will likely have far-reaching implications for the way Medicare negotiates drug prices in the US.